Drugs / BM-ECs
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02993809 Comparator | Mar 2018 → Dec 2019 | limb ischemia, peripheral vascular disease, ulcer of lower limbs | South China Research Center for Stem Cell and Regenerative Medicine | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM-ECs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02993809 ↗ |
| Known as | bone marrow derived endothelial cells | “bone marrow derived endothelial cells (BM-ECs)” NCT02993809 ↗ |
| Modality | Cell therapy | “autologous bone marrow derived endothelial cells (BM-ECs)” NCT02993809 ↗ |
| Route | Intramuscular | “Multipoint of intramuscular injections into ischemic limbs.” NCT02993809 ↗ |